Estimation of General Practitioner Visits, Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus and Influenza Virus, and Costs Associated With Hospitalizations, in Older Adults in France From 2010 to 2020 - Scorecard - MDSpire

Estimation of General Practitioner Visits, Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus and Influenza Virus, and Costs Associated With Hospitalizations, in Older Adults in France From 2010 to 2020

  • By

  • Charles Nuttens

  • Vanessa Barbet

  • Clélia Bignon-Favary

  • Emilie Lambourg

  • Stéphane Fiévez

  • Emmanuelle Blanc

  • Mathias Vacheret

  • Hervé Liliu

  • Philippe Vanhems

  • Jean-Sébastien Casalegno

  • Laurence Watier

  • Paul Loubet

  • Caihua Liang

  • Elizabeth Begier

  • Magali Lemaitre

  • December 5, 2025

  • 0 min

Share

Clinical Scorecard: Assessment of GP Consultations, Hospital Admissions, and Mortality Linked to Respiratory Syncytial Virus and Influenza in Older Adults in France from 2010 to 2020, Alongside Hospitalization-Related Costs

At a Glance

CategoryDetail
ConditionRespiratory syncytial virus (RSV) and influenza virus infections causing respiratory and cardiorespiratory illness
Key MechanismsViral respiratory infections leading to mild flu-like symptoms or severe respiratory complications, decompensation of underlying diseases, and death in vulnerable populations
Target PopulationFrench adults aged ≥50 years, with focus on those aged ≥65 years
Care SettingGeneral practitioner (GP) consultations, hospital admissions, and mortality surveillance in primary and hospital care settings

Key Highlights

  • RSV infection in adults ≥65 years responsible for approximately 647,619 GP visits, 24,319 hospitalizations, and 878 deaths annually in France.
  • GP visit incidence rates for RSV were twice those for influenza; hospitalization rates were similar, but RSV mortality was lower than influenza.
  • Mean annual cost of RSV-attributable hospitalizations was estimated at €105 million, comparable to influenza-related hospitalization costs.

Guideline-Based Recommendations

Diagnosis

  • Recognize that RSV burden in adults is underestimated due to non-specific symptoms and infrequent standard-of-care testing.
  • Use time-series regression modeling and viral activity data to estimate RSV and influenza attributable events.
  • Consider both respiratory and cardiorespiratory ICD-10 codes for comprehensive diagnosis and surveillance.

Management

  • Monitor vulnerable populations such as older adults and those with comorbidities closely for respiratory viral infections.
  • Anticipate potential cardiac complications in adults hospitalized with RSV or influenza infections.
  • Prepare for vaccination campaigns targeting RSV to reduce disease burden in older adults.

Monitoring & Follow-up

  • Utilize GP electronic medical records and national hospital databases for ongoing surveillance of RSV and influenza incidence.
  • Track hospitalizations and mortality rates stratified by age and diagnosis type to assess disease impact.
  • Evaluate hospitalization costs to inform healthcare resource allocation.

Risks

  • Increased risk of severe respiratory complications and death in older adults and those with underlying conditions.
  • Elevated risk of acute cardiovascular events in adults hospitalized with RSV or influenza infections.
  • Underdiagnosis and underreporting of RSV due to diagnostic limitations and coding inaccuracies.

Patient & Prescribing Data

Adults aged ≥50 years in France, especially those ≥65 years

RSV and influenza infections cause significant healthcare utilization; vaccination and early detection may reduce hospitalizations and associated costs.

Clinical Best Practices

  • Incorporate comprehensive viral testing and accurate ICD-10 coding to improve RSV diagnosis in adults.
  • Apply time-series modeling approaches to estimate viral disease burden for informed public health decisions.
  • Focus preventive strategies, including vaccination, on older adults to mitigate RSV and influenza impact.
  • Monitor for cardiac complications in patients hospitalized with respiratory viral infections.
  • Use cost data to guide resource planning and evaluate the economic impact of RSV and influenza.

References

Original Source(s)

Related Content